BioSpace News Archive

Milliman, Inc. today announced the acquisition of Torch Insight® from Leavitt Partners, LLC.

Beltone, the nation’s leading hearing care retailer with more than 1,500 locations in North America, today announced Beltone Imagine™ (www.beltone.com), a truly made-to-measure hearing aid

VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO SSI in patients with colorectal cancer. The study, “Assessment of QBECO SSI on Immunological Parameters in the Tumor Microenvironment and Sy

MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) integrating US and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, and Quality Assurance, is pleased to announce the expansion of its neurological franchise.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020. Presentation Details Panel Title: Stronger Together: Continuing industry and patient partnerships

Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease

While granting the pharma company exclusivity for specific ocular targets, Everads has retained the right to work on other targets and treatments, both independently and with other partners.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that it has received approval from Australia’s Therapeutic Goods Administration for the supply of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses.

Vanda Pharmaceuticals Inc. reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 pneumonia in the ODYSSEY study.

• ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors • Clinical trial expected to enroll up to 24 patients across the U.S. SAN FRANCISCO and TAIPEI, Taiwan, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that it has dosed the first patient in its Phase 1 open-label, dose escalatio